Zealand Pharma A/S (ZLDPF)
OTC PINK OTC PINK Primary 
Zealand Pharma A/S (ZLDPF) Analyst/Investor Day Transcript
Zealand Pharma A/S (ZLDPF) Analyst/Investor Day Transcript
Zealand Pharma to accelerate drug development for obesity, metabolic disease
Danish biotech Zealand Pharma said on Thursday it will accelerate development and expand its research as it seeks to differentiate its experimental obesity drug candidates in an increasingly competitive race to treat metabolic health issues.
Zealand Pharma A/S (ZLDPF) Q3 2025 Earnings Call Transcript
Zealand Pharma A/S (OTCPK:ZLDPF) Q3 2025 Earnings Call November 13, 2025 8:00 AM EST Company Participants Adam Steensberg - President & CEO David Kendall - Executive VP, Chief Medical Officer & Head of R&D Henriette Wennicke - EVP & CFO Conference Call Participants Kirsty Ross-Stewart - BNP Paribas, Research Division Hakon Hemme Jørgensen - Danske Bank A/S, Research Division Lucy-Emma Codrington-Bartlett - Jefferies LLC, Research Division Tsan-Yu Hsieh - William Blair & Company L.L.C., Research Division Kerry Holford - Joh.
Zealand Pharma scraps obesity drug candidate, citing crowded market, Bloomberg News reports
Zealand Pharma is halting development of a potential next-generation obesity drug after concluding the market has become too crowded for it to stand out, Bloomberg News reported on Thursday, citing an interview with the company CEO.
Zealand Pharma A/S (ZLDPF) Q2 2025 Earnings Call Transcript
Zealand Pharma A/S (OTCPK:ZLDPF) Q2 2025 Earnings Call August 14, 2025 8:00 AM ET Company Participants Adam Langer - Corporate Participant Adam Sinding Steensberg - President & CEO David M. Kendall - Executive VP, Chief Medical Officer & Head of R&D Henriette Wennicke - EVP & CFO Conference Call Participants Benjamin Jackson - Jefferies LLC, Research Division Carsten Lønborg Madsen - Danske Bank A/S, Research Division Jacob Mekhael - KBC Securities NV, Research Division Kirsty Ross-Stewart - BNP Paribas Exane, Research Division Michael Novod - Nordea Markets, Research Division Prakhar Agrawal - Cantor Fitzgerald & Co., Research Division Rajan Sharma - Goldman Sachs Group, Inc., Research Division Rei Tan - BTIG, LLC, Research Division Sophia Graeff Buhl Nielsen - JPMorgan Chase & Co, Research Division Tsan-Yu Hsieh - William Blair & Company L.L.C.
Zealand Pharma A/S (ZLDPF) Q1 2025 Earnings Call Transcript
Zealand Pharma A/S (OTCPK:ZLDPF) Q1 2025 Earnings Conference Call May 8, 2025 8:00 AM ET Company Participants Adam Lange - Vice President, Investor Relations Adam Steensberg - President & Chief Executive Officer David Kendall - Chief Medical Officer Henriette Wennicke - Chief Financial Officer Eric Cox - Chief Commercial Officer Conference Call Participants Michael Novod - Nordea Andy Hsieh - William Blair Prakhar Agrawal - Cantor Fitzgerald Chiara Montironi - Van Lanschot Kempen Charlie Haywood - Bank of America Shan Hama - Jefferies Ollie Burrow - Goldman Sachs Adam Lange Thank you to everyone for joining us today to discuss Zealand Pharma's results for the First Three Months of 2025. You can find the related company announcements on our website at zealandpharma.com.
Zealand Pharma AS (ZLDPF) Stock Jumps 8.0%: Will It Continue to Soar?
Zealand Pharma AS (ZLDPF) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Zealand Pharma's new drug petrelintide will help people lose weight: CEO
Zealand Pharma CEO Adam Steensberg discusses the company's new collaboration and licensing agreement with Roche as well as the commercial opportunities for its amylin analog molecule.
Zealand Pharma A/S (ZLDPF) Q4 2024 Earnings Call Transcript
Zealand Pharma A/S (OTCPK:ZLDPF) Q4 2024 Earnings Conference Call February 20, 2025 8:00 AM ET Company Participants Anna Krassowska - VP, IR Adam Steensberg - President and Chief Executive Officer David Kendall - Executive Vice President, Chief Medical Officer Henriette Wennicke - Executive Vice President, Chief Financial Officer Eric Cox - Executive Vice President, Chief Commercial Officer Conference Call Participants James Gordon - JPMorgan Charlie Hayward - Bank of America Merrill Lynch Michael Novod - Nordea Prakhar Agrawal - Cantor Rajan Sharma - Goldman Sachs Benjamin Jackson - Jefferies Thomas Franken - KBC Securities Kerry Holford - Berenberg Laura Hindley - Morgan Stanley Jesper Ilsøe - Carnegie Operator Welcome to the Zealand Pharma Results for Full Year 2024 Conference Call. [Operator Instructions].
Zealand Pharma CEO says Novo's CagriSema data supports monotherapy approach to cagrilintide
The CEO of Danish drugmaker Zealand Pharma said on Friday that data posted by Novo Nordisk's late-stage study of its next-generation obesity drug CagriSema supported Zealand's own monotherapy approach to cagrilintide.
US FDA declines to approve Zealand Pharma's bowel disease drug
The U.S. Food and Drug Administration declined to approve Zealand Pharma's bowel disease drug, the company said on Thursday.
Zealand Pharma starts Phase 2b trial for obesity drug candidate petrelintide
Danish biotechnology company Zealand Pharma said on Tuesday it had enrolled the first patient in its so-called Phase 2b ZUPREME-1 trial with its obesity treatment candidate petrelintide.
